Exozymes

EXOZNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$47.018 M

$5.11 -1.17%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$9.16M

Loss-making

Shares outstanding

8,478,992

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#129Atyr PharmaATYR$50.1M
#130Black Hawk AcquisitionBKHA$48.9M
#131ExozymesEXOZ$47.0M
#132Metagenomi TherapeuticsMGX$46.3M
#133TevogenTVGN$41.5M

Where these numbers come from

Share counts and financials for Exozymes are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.